What Is Copper-67 and How Is It Used in Medicine?

Copper-67 is a radioactive form of copper that emits both beta particles and gamma rays, a combination that lets it destroy cancer cells while simultaneously producing images doctors can use to track where the treatment is going. With a half-life of about 61.8 hours, it stays active in the body long enough to accumulate in tumors but clears within days, striking a balance that researchers have pursued for decades but only recently begun to exploit at clinical scale. The isotope sits at the center of growing interest in “theranostic” medicine, where a single agent serves double duty as both diagnostic tool and therapy, and its story involves hard physics, creative chemistry, and a supply problem that has shaped the entire field.

Why Two Types of Radiation Matter

Copper-67 decays by emitting beta-minus particles with a maximum energy of about 562 keV, along with gamma rays at 93 keV and 185 keV.¹ The beta particles travel only a few millimeters in tissue before depositing their energy, which is exactly what you want for killing tumor cells without shredding everything nearby. The gamma rays, meanwhile, pass through the body and can be picked up by a SPECT camera, producing three-dimensional images of where the isotope has concentrated. This means a doctor can inject a copper-67-labeled drug, image the patient to confirm the drug reached the tumor, and know that therapeutic radiation is being delivered at the same time.²

The half-life matters here too. At roughly 2.6 days, copper-67 gives an antibody-based drug enough time to circulate, find its target, and bind before the isotope has decayed away. Faster-decaying isotopes may burn out before the drug reaches the tumor; slower ones linger and irradiate healthy tissue unnecessarily. The precision measurement of copper-67’s half-life, pinned down to 61.761 ± 0.004 hours, reflects just how carefully researchers have characterized this isotope for medical dosimetry.³

The Copper-64 and Copper-67 Theranostic Pair

One of the most compelling features of copper-67 is that it has a sibling isotope, copper-64, that emits positrons suitable for PET imaging. Because both isotopes are the same element, they behave identically in chemical reactions. You can attach copper-64 to a drug molecule, inject it, and take a PET scan to see whether the drug reaches the tumor and how it distributes through the body. If it does what you want, you swap in copper-67 using the exact same chemistry and deliver the therapeutic dose. The diagnostic scan predicts the therapy’s behavior with unusual accuracy because the two isotopes ride the same molecular vehicle to the same destination.⁴

This “matched pair” concept is a significant advantage over theranostic approaches that rely on isotopes of different elements for imaging and therapy. When different metals are involved, you need different chelators or different labeling conditions, and the resulting drugs may not distribute identically in the body. With copper-64 and copper-67, the chelator, the labeling process, and the pharmacokinetics stay the same, reducing variability in the supply chain and simplifying the path from diagnosis to treatment.⁵ Work in HER2-positive gastric cancer has demonstrated this approach using trastuzumab, the same antibody used in conventional Herceptin therapy, labeled first with copper-64 for imaging and then copper-67 for treatment.

How Copper-67 Is Made

Producing copper-67 in useful quantities has been the single biggest obstacle to its clinical use. Unlike some medical isotopes that can be made in standard hospital cyclotrons, copper-67 production traditionally required specialized facilities, and for years the supply was so limited that only a handful of research groups could get their hands on it.

The most established method uses a photonuclear reaction: high-energy photons (bremsstrahlung radiation from an electron accelerator) bombard enriched zinc-68 targets, knocking out a neutron and a proton to produce copper-67. Argonne National Laboratory’s low-energy accelerator facility has been routinely producing the isotope this way, delivering roughly one curie per batch with radionuclidic purity above 99%.⁶ Using enriched target material is essential in this process to avoid co-producing contaminant isotopes like zinc-65 and copper-64 that would compromise the product’s purity.

A newer approach uses medical cyclotrons, the same machines already installed at many hospitals for making PET isotopes. By firing protons at enriched zinc-70 targets, researchers can produce copper-67 through a different nuclear reaction. One group demonstrated production of up to 600 MBq of copper-67 per run at a 30 MeV cyclotron, achieving radionuclidic purity over 99.5%.⁷ Other teams have been working to establish cross-section data and thick-target yields for lower-energy proton beams in the 14 to 16.5 MeV range, which would make production feasible on even smaller cyclotrons commonly found in clinical settings.⁸

The cyclotron route is particularly promising because it could decentralize production. Instead of shipping a decaying isotope across the country from one national lab, hospitals could potentially make copper-67 on site. That said, as of recent reviews, commercial suppliers were not yet online, and scaling up production to meet what would be massive clinical demand remains an active challenge.

Cancers Being Targeted With Copper-67

Researchers have tested copper-67-labeled drugs against a range of cancers, often by attaching the isotope to antibodies or small molecules that home in on specific proteins found on tumor cells. The breadth of targets under investigation reflects the versatility of the isotope itself.

Prostate Cancer

Prostate-specific membrane antigen, or PSMA, is heavily expressed on prostate cancer cells and has become one of the most actively pursued targets in nuclear medicine. A bivalent PSMA-targeting ligand labeled with copper-67 showed dose-dependent tumor growth inhibition in animal models, performing comparably to lutetium-177-labeled PSMA agents that are already in clinical use.⁹ Survival was similar whether the drug was given as a single dose or split into two fractions. Separate work has developed PSMA ligands that also bind to serum albumin, a trick that extends the drug’s circulation time and increases tumor exposure.¹⁰

Lymphoma

Copper-67’s history in lymphoma research stretches back decades. Early studies in the late 1980s demonstrated that a copper-67-labeled antibody called Lym-1, targeting B-cell lymphoma, achieved significant tumor uptake in animal models, with radioactivity continuously clearing from normal tissues while persisting in the tumor over 120 hours.¹¹ This work eventually progressed to human patients with non-Hodgkin’s lymphoma, where copper-67-labeled Lym-1 delivered roughly twice the radiation dose to tumors compared with the same antibody labeled with iodine-131. Tumor concentration of the copper-67 version was 1.7 to 2.8 times higher at various time points, and the therapeutic index (the ratio of tumor dose to bone marrow dose) was about three times more favorable: 29 for copper-67 versus 9.7 for iodine-131.¹²

Neuroblastoma and Other Solid Tumors

In a preclinical model of neuroblastoma that had spread to the liver, copper-67-SARTATE therapy started two weeks after tumor cell implantation extended survival by about 30% compared to untreated animals.¹³ This study is interesting because it specifically tested the drug against minimal residual disease, the tiny clusters of cancer cells left behind after initial treatment that often seed relapse. Breast cancer models have also been explored using copper-67-labeled trastuzumab, and early-stage work is targeting HER2-positive gastric cancers with similar agents.

How Copper-67 Compares to Other Therapeutic Isotopes

Copper-67 is not the only beta-emitting isotope being developed for targeted radionuclide therapy. Lutetium-177 is the current clinical workhorse, already FDA-approved for neuroendocrine tumors and prostate cancer. Iodine-131 has been used for thyroid cancer for decades. Yttrium-90 is used in liver-directed therapy. So where does copper-67 fit?

Against iodine-131, the comparison in lymphoma patients is instructive. The copper-67 version of the Lym-1 antibody stayed in tumors much longer (biological half-time of 8.8 days vs. 2.3 days for iodine-131) and achieved a significantly better therapeutic index.¹⁴ One caveat: the liver received a higher radiation dose from the copper-67 formulation than from iodine-131, a pattern that has appeared consistently across studies and is something clinicians would need to manage.¹⁵

Against other beta emitters in a different kind of comparison, dosimetry modeling has shown that copper-67 performs well for tumors at least a few millimeters across. For larger tumor deposits (5 mm and up), copper-67, scandium-47, and terbium-161 all deliver comparable absorbed doses. But as tumors shrink below about 1 mm, copper-67’s beta particles start to overshoot the target, depositing energy outside the tiny lesion. Terbium-161, which emits lower-energy electrons alongside its beta particles, maintains higher doses in these micrometastases. In a 100-micrometer cluster of tumor cells, terbium-161 delivered roughly 45 Gy compared to about 24 Gy from copper-67.¹⁶ This does not make copper-67 inferior; it means the choice of isotope may eventually depend on tumor size and distribution.

Keeping the Isotope Where It Belongs

A radioactive isotope is only useful if it stays attached to the drug that carries it to the tumor. If copper-67 breaks free from its molecular carrier while circulating in the blood, it gets picked up by the liver or kidneys, irradiating healthy organs instead of cancer. This is where chelator chemistry comes in: the chelator is the molecular cage that grips the copper ion and holds it tight.

Early chelators used with copper isotopes were not always up to the job. Studies of antibody-chelator conjugates found that by day five, a copper-containing protein fragment appeared in the liver, likely because copper had escaped from the chelator and bound to the body’s own proteins, possibly superoxide dismutase.¹⁷ This transchelation, as researchers call it, appeared to be the main driver of unwanted liver accumulation.

Sarcophagine chelators, a class of cage-like molecules, have largely addressed this problem. They form exceptionally stable complexes with copper and can be loaded with the isotope at room temperature in minutes, a practical advantage when you are working with a decaying radioactive material and every hour counts.¹⁸ The drug Cu-SARTATE, which pairs a sarcophagine chelator with a somatostatin receptor-targeting peptide, has been the vehicle for several of the preclinical studies mentioned earlier and is one of the more clinically advanced copper-67 agents.

Specific Activity and Dose-Response

Not all preparations of copper-67-labeled drugs are equally effective, even at the same total radioactivity. What matters is specific activity, the amount of radioactivity per unit of drug. If a preparation contains a lot of “cold” (non-radioactive) antibody alongside the labeled antibody, those cold molecules compete for binding sites on the tumor. The radioactive molecules may get crowded out, reducing the dose that actually reaches the cancer.

This was demonstrated clearly in a study using copper-67-labeled pertuzumab (an anti-HER2 antibody). Mice receiving a high specific activity preparation showed better tumor accumulation and more effective tumor growth inhibition than those given the same total radioactivity at lower specific activity, where excess cold antibody saturated the tumor’s binding sites.¹ The same study showed that dose escalation had limits: while the lowest dose tested (3.7 MBq) was well tolerated with only temporary weight loss, higher doses caused significant toxicity, and the highest dose group (14.8 MBq) survived only about 12 days on average. This kind of steep dose-response curve underscores why the imaging component of a theranostic approach is so valuable. Seeing where the drug goes and how much accumulates in the tumor versus healthy tissue helps clinicians choose a dose that is therapeutic without being lethal.

Combining Copper-67 With Immunotherapy

One of the more exciting recent directions is using copper-67-based therapy to prime tumors for immunotherapy. Some cancers, particularly small cell lung cancer, are considered immunologically “cold,” meaning the immune system largely ignores them and checkpoint inhibitor drugs have limited effect on their own. Targeted radiation may change that by damaging tumor cells in ways that make them more visible to the immune system.

In a small cell lung cancer model, combining copper-67-SARTATE with both anti-PD-L1 and anti-CTLA4 checkpoint inhibitors improved median survival by 13 days compared to animals receiving only saline, by 7 days compared to copper-67-SARTATE alone, and by 3 days compared to immunotherapy alone.¹⁹ The researchers interpreted this as evidence that targeted radiation was converting cold tumors into ones the immune system could attack, a synergy that neither approach achieved as effectively alone. If this holds up in further studies, it could open a role for copper-67 not just as a stand-alone cancer killer but as a partner to the immunotherapy drugs that have transformed oncology over the past decade.

The Supply and Regulatory Picture

For all its promise, copper-67’s path to routine clinical use depends on solving practical problems that go beyond biology. Large-scale isotope supply remains a hurdle: enriched zinc-68 and zinc-70 target materials are expensive, the number of facilities capable of producing clinical-grade copper-67 is still small, and the 2.6-day half-life means the isotope cannot be stockpiled. Every batch is a race against the clock from production through purification, quality control, shipping, and administration.

On the regulatory side, the copper-64/copper-67 pair has been recognized as a chemically matched theranostic system that could streamline the pathway from diagnostic imaging to therapy, since the two isotopes use identical chemistry and the diagnostic scan directly predicts the therapeutic distribution. Regulatory frameworks for radiopharmaceuticals are evolving to accommodate theranostic agents, though challenges remain in harmonizing standards across countries and ensuring that production can scale to meet what would be substantial demand if clinical trials succeed. Commercial entities have signaled interest in the photonuclear production route, and the cyclotron-based approach could eventually bring production closer to the point of care, but neither pathway has yet reached the kind of industrial-scale availability that lutetium-177 now enjoys.